Biological medicines, also known as biopharmaceuticals or biologics, have changed modern medicine with their targeted mechanisms and highly effective treatments.

On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its independently developed innovative product, GB18.

May 19 is designated as World Inflammatory Bowel Disease (IBD) Day, aimed at raising public awareness of IBD patients and improving their quality of life and medical care.

When global pharmaceutical companies or health sector enterprises search for a Chinese biological products factory, one name consistently stands out: Kexing Biopharm.

Biopharmaceuticals, also known as biologics, have redefined the landscape of modern medicine.

The biopharmaceutical industry is undergoing a transformative era, driven by cutting-edge research, technological advancements, and an increasing demand for novel therapies.

Synthetic biology is an emerging interdisciplinary field that integrates knowledge and techniques from biology, genomics, engineering, and informatics.